ERBB2 and breast neoplasm: Ongoing phase 2 (NCT03248492) and phase 3 trials are evaluating trastuzumab deruxtecan in patients with HER2-positive advanced breast cancer (NCT03523585, NCT03529110) and in HER2-low breast tumors (NCT03734029).